Maxcyte Stock Performance
| MXCT Stock | USD 0.91 0 0.33% |
The company secures a Beta (Market Risk) of 1.67, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, MaxCyte will likely underperform. At this point, MaxCyte has a negative expected return of -0.85%. Please make sure to verify MaxCyte's potential upside, rate of daily change, as well as the relationship between the Rate Of Daily Change and period momentum indicator , to decide if MaxCyte performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days MaxCyte has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's fundamental indicators remain comparatively stable which may send shares a bit higher in March 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
1 | MaxCyte CFO to step down in first half of 2026 | 11/12/2025 |
2 | MaxCyte Inc Q3 2025 Earnings Call Highlights Strategic Moves Amidst Market Challenges | 11/13/2025 |
3 | How MaxCyte Inc. stock reacts to fiscal policies - July 2025 Selloffs Risk Controlled Daily Plans - newser.com | 11/19/2025 |
4 | Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnershi... | 12/01/2025 |
5 | How sustainable is MaxCyte Inc. stock dividend payout - Long Setup Comprehensive Market Scan Insights - DonanmHaber | 12/19/2025 |
6 | Will MaxCyte Inc. stock deliver strong dividend growth - 2026 world cup usa national team group stage defensive leaders pressing system tactical prediction guid... | 01/06/2026 |
7 | Acquisition by Collins Cynthia of 97698 shares of MaxCyte at 3.87 subject to Rule 16b-3 | 01/29/2026 |
| Begin Period Cash Flow | 46.5 M | |
| Total Cashflows From Investing Activities | 6.9 M |
MaxCyte Relative Risk vs. Return Landscape
If you would invest 161.00 in MaxCyte on November 4, 2025 and sell it today you would lose (70.30) from holding MaxCyte or give up 43.66% of portfolio value over 90 days. MaxCyte is currently does not generate positive expected returns and assumes 3.7977% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than MaxCyte, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
MaxCyte Target Price Odds to finish over Current Price
The tendency of MaxCyte Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.91 | 90 days | 0.91 | close to 99 |
Based on a normal probability distribution, the odds of MaxCyte to move above the current price in 90 days from now is close to 99 (This MaxCyte probability density function shows the probability of MaxCyte Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.67 . This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, MaxCyte will likely underperform. Additionally MaxCyte has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. MaxCyte Price Density |
| Price |
Predictive Modules for MaxCyte
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as MaxCyte. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of MaxCyte's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
MaxCyte Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. MaxCyte is not an exception. The market had few large corrections towards the MaxCyte's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold MaxCyte, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of MaxCyte within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.79 | |
β | Beta against Dow Jones | 1.67 | |
σ | Overall volatility | 0.19 | |
Ir | Information ratio | -0.2 |
MaxCyte Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of MaxCyte for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for MaxCyte can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| MaxCyte generated a negative expected return over the last 90 days | |
| MaxCyte has some characteristics of a very speculative penny stock | |
| MaxCyte has high historical volatility and very poor performance | |
| MaxCyte has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 38.63 M. Net Loss for the year was (41.05 M) with profit before overhead, payroll, taxes, and interest of 27.53 M. | |
| MaxCyte currently holds about 240.89 M in cash with (27.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.37, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 75.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Collins Cynthia of 97698 shares of MaxCyte at 3.87 subject to Rule 16b-3 |
MaxCyte Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of MaxCyte Stock often depends not only on the future outlook of the current and potential MaxCyte's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. MaxCyte's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 104.8 M | |
| Cash And Short Term Investments | 154.5 M |
MaxCyte Fundamentals Growth
MaxCyte Stock prices reflect investors' perceptions of the future prospects and financial health of MaxCyte, and MaxCyte fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MaxCyte Stock performance.
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (1.33) % | ||||
| Operating Margin | (1.62) % | ||||
| Current Valuation | 17.05 M | ||||
| Shares Outstanding | 106.67 M | ||||
| Price To Book | 0.54 X | ||||
| Price To Sales | 2.81 X | ||||
| Revenue | 38.63 M | ||||
| Gross Profit | 27.53 M | ||||
| EBITDA | (46.41 M) | ||||
| Net Income | (41.05 M) | ||||
| Cash And Equivalents | 240.89 M | ||||
| Cash Per Share | 2.37 X | ||||
| Total Debt | 18.03 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 14.24 X | ||||
| Book Value Per Share | 1.69 X | ||||
| Cash Flow From Operations | (27.61 M) | ||||
| Earnings Per Share | (0.43) X | ||||
| Market Capitalization | 96.73 M | ||||
| Total Asset | 239.47 M | ||||
| Retained Earnings | (216.85 M) | ||||
| Working Capital | 155.91 M | ||||
About MaxCyte Performance
Assessing MaxCyte's fundamental ratios provides investors with valuable insights into MaxCyte's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the MaxCyte is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 412.43 | 375.25 | |
| Return On Tangible Assets | (0.15) | (0.16) | |
| Return On Capital Employed | (0.26) | (0.25) | |
| Return On Assets | (0.15) | (0.16) | |
| Return On Equity | (0.23) | (0.22) |
Things to note about MaxCyte performance evaluation
Checking the ongoing alerts about MaxCyte for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for MaxCyte help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MaxCyte generated a negative expected return over the last 90 days | |
| MaxCyte has some characteristics of a very speculative penny stock | |
| MaxCyte has high historical volatility and very poor performance | |
| MaxCyte has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 38.63 M. Net Loss for the year was (41.05 M) with profit before overhead, payroll, taxes, and interest of 27.53 M. | |
| MaxCyte currently holds about 240.89 M in cash with (27.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.37, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 75.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Collins Cynthia of 97698 shares of MaxCyte at 3.87 subject to Rule 16b-3 |
- Analyzing MaxCyte's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MaxCyte's stock is overvalued or undervalued compared to its peers.
- Examining MaxCyte's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MaxCyte's management team can have a significant impact on its success or failure. Reviewing the track record and experience of MaxCyte's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MaxCyte's stock. These opinions can provide insight into MaxCyte's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for MaxCyte Stock Analysis
When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.